

Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic Review

Nicholas W. Carris,^{1,2} Joe Pardo,⁴ Jose Montero,³ and Kristy M. Shaeer^{1,3}

¹Department of Pharmacotherapeutics and Clinical Research, University of South Florida College of Pharmacy, Departments of ²Family Medicine, ³Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa; and ⁴Department of Pharmacy, North Florida/South Georgia Veterans Health System, Gainesville

Doxycycline, a commonly prescribed tetracycline, remains on intermittent shortage. We systematically reviewed the literature to assess minocycline as an alternative to doxycycline in select conditions, given doxycycline's continued shortage. We identified 19 studies, 10 of which were published before 2000. Thirteen of the studies were prospective, but only 1 of these studies was randomized. Based on the available data, we found minocycline to be a reasonable substitute for doxycycline in the following scenarios: skin and soft-tissue infections and outpatient treatment of community-acquired pneumonia in young, otherwise healthy patients or in patients with macrolide-resistant *Mycoplasma pneumoniae*, as well as Lyme disease prophylaxis and select rickettsial disease should doxycycline be unavailable.

Keywords. alternatives; doxycycline; minocycline; shortage; substitution.

Antibacterial drug shortages are a growing interference in the clinical management of infectious diseases [1–4]. Close to 150 antibacterial agents experienced shortages between 2001 and 2013, with nearly one quarter of these drugs experiencing more than 1 shortage [2]. The impact of a drug shortage is felt at the patient-physician interface and on the institutional level. Seventy-eight percent of infectious diseases physicians surveyed reported that antimicrobial shortages have had a negative impact on their practice [5]. Furthermore, the difficulty of drug procurement during a shortage is often compounded by a substantial price increase for the products that remain on the market. Members of the US Congress have deliberated over how to assure the availability of clinically important generic drugs in the setting of shortage-driven market manipulations [4]. A centerpiece of congressional discussions was the example of oral doxycycline. Doxycycline, a tetracycline antibiotic with myriad labeled

indications, experienced a 2000% increase in average retail price between 2012 and 2013 [6], and currently the list price for doxycycline is as high as \$19 per capsule in our network. In the face of an inconsistent and steeply priced doxycycline supply, institutions have been forced to consider alternate therapies. Minocycline has emerged as a candidate to bridge therapeutic gaps and conserve financial resources, potentially serving as a simple substitute across a broad range of indications. The objective of this review was to summarize available study evidence and identify a clinical role for minocycline in light of the current or future shortages of doxycycline.

TETRACYCLINE OVERVIEW

Pharmacology and Pharmacokinetics

Tetracycline antibiotics exert their antibacterial action by disruption of protein synthesis. This is accomplished through reversible binding to the 30S subunit of the bacterial ribosome, which interferes with the interaction between aminoacyl transfer-RNA and messenger RNA [7, 8]. Doxycycline and minocycline are both second-generation tetracyclines with similar chemical structures (Figure 1) [7–9]. Minocycline is distinguished by minor structural differences at carbons 5 and 6 and the addition of a dimethylamino group at position 7 [8, 10].

Received 19 October 2015; accepted 11 November 2015.

Correspondence: Joe Pardo, PharmD, BCPS, AAHIVP, 1601 SW Archer Road, Gainesville, FL 32608-1197 (joseph.pardo@va.gov).

Open Forum Infectious Diseases

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

DOI: 10.1093/ofid/ofv178




Figure 1. Molecular structures of doxycycline and minocycline [7, 9].

These structural differences enhance the lipophilicity of minocycline compared with other tetracycline antibiotics. Both agents are between 90% and 100% bioavailable when taken orally, although absorption is impaired when coadministered with divalent and trivalent cations. Approximately 30%–65% of doxycycline is renally eliminated, with the remaining excretion occurring in the feces and bile [11–14]. In contrast, minocycline undergoes hepatic biotransformation. Metabolites and unchanged drug are eliminated in the urine and feces, with only 10% of the parent compound recovered unchanged in the urine.

Adverse Drug Reactions

The most common adverse drug reactions (ADRs) are characteristic of the tetracycline class: gastrointestinal disturbances, esophagitis, photosensitivity, pediatric tooth discoloration, and, rarely, hepatotoxicity, hypersensitivity, and idiopathic intracranial hypertension. Minocycline is more likely to cause other central nervous system effects (eg, dizziness, lack of concentration, ataxia, vertigo, tinnitus associated with weakness, nausea, and vomiting) and pigmentation of various body sites [8]. Overall, ADRs are reported more frequently for minocycline, but both drugs are generally well tolerated. The comparative safety of doxycycline and minocycline has been reviewed in detail previously [15].

Spectrum of Activity

Doxycycline and minocycline have comparable in vitro activity. Their antibacterial spectrum encompasses commonly isolated Gram-positive and Gram-negative bacteria (eg, staphylococci, streptococci, certain *Enterobacteriaceae*). In addition, activity is noted against atypical pathogens involved in pulmonary and sexually transmitted infections, *Rickettsia*, and the infectious agents of other less common syndromes (eg, brucellosis, melioidosis, leptospirosis, anthrax, plague, and Q fever). Minocycline has emerged as the tetracycline of choice for multidrug-resistant *Acinetobacter baumannii* infections, although doxycycline has also demonstrated activity. The use of tetracyclines for *A baumannii* infections was recently reviewed [16].

Clinical Efficacy

The clinical efficacy of minocycline should be critically evaluated before recommending direct therapeutic substitution for doxycycline. To our knowledge, this review is the first of its kind assessing the potential for minocycline use or substitution for doxycycline in targeted clinical scenarios. Because doxycycline can be used in the treatment of more than 30 different conditions and infections, we elected to review clinical data regarding minocycline in 4 specific scenarios, which were chosen a priori [9]. Skin and soft-tissue infections (SSTIs) and community-acquired pneumonia (CAP) were chosen for review because they are 2 of the most common infections that can be treated with tetracyclines [17, 18]. Lyme disease prophylaxis and the treatment of rickettsial disease were chosen for review because there is a limitation in the guidance previously provided by the Centers for Disease Control and Prevention (CDC) should doxycycline be entirely unavailable [1].

METHODS

Search Strategy and Selection Criteria

We searched Medline through PubMed and EMBASE via Ovid (up to August 20, 2015) for publications in English related to minocycline's use in SSTIs, CAP, tickborne rickettsial disease, and Lyme disease. We included publications if they reported original data from prospective clinical trials, prospective cohorts, or retrospective cohorts or cases series with ≥ 10 patients. We required clinical outcomes to be reported. The specific search terms we used were as follows: (minocycline [MeSH Terms] OR minocycline [Text Word]) AND (pneumonia [Text Word] OR pneumonia [MeSH Terms] OR soft tissue infection [MeSH Terms] OR soft tissue infection [Text Word] OR Rickettsia [Text Word] OR Rickettsia [MeSH Terms] OR Rocky Mountain Spotted Fever [Text Word] OR Rocky Mountain Spotted Fever [MeSH Terms] OR Ehrlichiosis [Text Word] OR Ehrlichiosis [MeSH Terms] OR Anaplasmosis [Text Word] OR Anaplasmosis [MeSH Terms] OR Lyme Disease [Text word] OR Lyme Disease [MeSH Terms]). Then, we reviewed the references of reports identified by this search for additional reports

to include. Finally, all investigators critically reviewed and searched medical literature for additional pertinent reports. These details represent the full protocol for study identification. Studies for inclusion were identified by 1 investigator (N.W.C.) and were confirmed by all coinvestigators. We resolved discrepancies by consensus.

Data Abstraction and Analysis

Data were abstracted after study eligibility was determined by the investigators. Data were abstracted using a standardized table (Table 1) and were corrected and confirmed by all investigators. The following information was retrieved: author, year, sample size, study design/setting, population, treatment, outcomes, and potential for bias. We elected not to perform a meta-analysis because inclusion was not limited based on study design and therefore included both retrospective and prospective studies, controlled and uncontrolled studies, and inpatient and outpatient studies over more than a 40-year period. We elected this systematic review method as a way to include all relevant clinical data rather than to significantly truncate an already small data set. A comparison to doxycycline was included if available; however, this was not required because the investigators sought to identify the potential utility of minocycline during doxycycline shortage rather than an alternative to doxycycline under circumstances of adequate supply. Therefore, our recommendations regarding the use of minocycline are placed into this context, based upon the data presented, developed in consideration of additional alternatives to doxycycline, and should be considered along with patient-specific factors, especially as they relate to potential ADRs.

RESULTS

Literature Review

The electronic search of Medline through PubMed identified 483 titles. Of the 43 reports [19–61] selected for full review, 23 reports [38–60] were excluded for reason before abstraction (Figure 2). One additional title [61] was excluded during record abstraction because key data were missing regarding the use of minocycline. The remaining 19 reports [19–37] are described in Table 1. No additional titles were identified through EMBASE. We identified 8 reports related to SSTIs [19–26], 5 related to CAP [26–30], 6 related to Lyme disease [31–36], and 1 related to rickettsial disease [37]. Six of the published reports were retrospective in nature, whereas 13 were prospective. Of the prospective studies, only 1 was randomized—however open-label—whereas an additional 6 included clinical outcomes on treatments in addition to minocycline. Published reports were from 1971 to 2013 and included outcome data on 336 patients treated with minocycline.

Skin and Soft Tissue Infections

In 3 of the studies regarding SSTIs, minocycline was dosed with an initial 200 mg loading dose, and 2 of those studies continued

therapy with minocycline 100 mg twice daily [20, 21], and the third study continued minocycline 100 mg once daily [19]. Three studies dosed minocycline 100 mg twice daily without a loading dose [23, 25, 26], 1 study dosed minocycline 100 mg twice daily or 200 mg twice daily [22], and the final study did not report specific dosing [24]. Cure rate was high (89%) in the 7 studies that reported cure specific to minocycline use [19–24, 26]. However, in 1 report [26], 2 of 6 (33%) patients with severe infection failed minocycline therapy. One patient was infected with an organism resistant to minocycline, and the other patient suffered from concurrent bacteremia. In contrast, the largest single report of minocycline use in SSTIs demonstrated cure in all 15 patients treated for severe *Staphylococcus aureus* infections [21]. Limitations of the data must be recognized. Only 4 studies were prospective, and none were randomized. The largest single report of minocycline use in SSTIs included only 15 patients. In addition, reports were generally limited in their description of nonpharmacologic treatments or in details regarding infection purulence. Therefore, the potential exists that some patients included in these reports may be treated differently based on current guidelines, that is, incision and drainage without systemic antibiotics. However, it should be noted that several of the studies did include patients with severe or complicated infections that would most likely require systemic antibiotics under current guidelines [19, 21, 22, 26].

Community-Acquired Pneumonia

All but 1 identified report focused on the treatment of *Mycoplasma pneumoniae* [26]. In addition, these reports were published recently, all from Japan, and primarily related to macrolide-resistant *M pneumoniae* [27–30]. All studies were prospective, although none were randomized. Three of the reports are exclusively related to pediatrics, whereas 1 included adults [30]. In all studies, the clinical outcome was defervescence, which occurred in a large proportion of patients (85%–100%). Three studies included treatments other than minocycline—eg, doxycycline, quinolones, and macrolides—and in each study, minocycline had the highest proportion of responders. However, comparisons should be made cautiously due to the observational nature of these studies. An additional limitation is that the majority of the studies focused on confirmed *M pneumoniae* rather than empiric treatment of CAP. The remaining report included patients with mixed pneumonia presentations, not exclusively CAP [26]. Although there was great heterogeneity in patient presentation, all were considered “severe”. All 14 patients achieved a satisfactory clinical response after intravenous minocycline therapy.

Lyme Disease Prophylaxis

No reports were identified that assessed Lyme disease prophylaxis with minocycline. The 6 included studies (all completed in Europe) assessed minocycline in the treatment of early

Table 1. Review of Literature on Patients Treated With Minocycline for Selected Diseases States

Study/Sample Size	Design/ Setting	Population/Condition/Age; Mean or Median (Range), Years	Reported Treatment(s)	Outcome(s) N (%)	Potential for Bias
Skin and soft tissue infections					
Cappel and Klastersky [19] N = 20	Retrospective/inpatient/ Belgium	Disseminated malignancy moderately severe (investigator reported) bacterial infection Age: 63 (25–77) SSTI, N = 11	Minocycline (route not reported) DOT: 7 d	Cure: 10/11 (91)	Retrospective; small sample size Minocycline dose lower than current standard Compromised patient population
Phair et al [20] N = 10	Prospective uncontrolled/ outpatient/United States	Purulent SSTI, identified <i>Staphylococcus aureus</i> Age: not reported	Minocycline (PO) DOT: 8–18 d Local soaks and debridement PRN	Cure: 8/10 (80)	Uncontrolled study Small sample size Limited description of nonpharmacologic intervention
Raff et al [21] N = 15	Prospective uncontrolled/ not reported/United States	Severe (investigator reported) <i>S aureus</i> SSTIs Age: 56 (22–83)	Minocycline (PO) DOT: 6–28 d	Cure: 15/15 (100)	Uncontrolled study Small sample size Limited description of nonpharmacologic intervention
Clumeck et al [22] N = 25	Prospective uncontrolled/ inpatient/Belgium	Severe <i>S aureus</i> infection; Age: 62 (18–88) SSTI, N = 4 Other cohort indications: PNA, osteomyelitis septic thrombophlebitis, febrile urinary tract infection, endocarditis, and liver abscess	Minocycline + rifampin Entire cohort (N = 25) description DOT: 5–119 d (mean 22) (PO, N = 20; IV, N = 5)	SSTI Cure: 3/4 (75)	Uncontrolled study; small sample size Limited description of nonpharmacologic intervention 21 patients received minocycline 100 mg Q12H, and 4 patients received 200 mg every Q12H
Ruhe et al [23] N = 24	Retrospective/inpatient/ United States	Serious, tetracycline-susceptible MRSA infection Age: 51 (28–94) Complicated SSTI, N = 16	Minocycline (PO); N = 5 Doxycycline (PO); N = 11	Cure: 5/5 (100) 10/11 (91)	Retrospective; small sample size Allowed alternative initial antibiotic if ≤50% of appropriate treatment duration DOT not reported specific to SSTI
Barnes et al [24] N = 30	Retrospective review with prospective observation/ outpatient/United States	Nonserious; MRSA-SSTI; cellulitis, abscess, or both Age: 46 (18–83)	Minocycline (PO) Doxycycline (PO) Trim/sulfa (PO) Clindamycin (PO) Drainage only β-lactam (PO) + drainage Fluoroquinolone (PO)	Cure: 3/3 (100) 1/1 (100) 6/6 (100) 8/8 (100) 4/4 (100) 5/5 (100) 3/3 (100)	Retrospective/observational; small sample size Dosing not reported; DOT not reported 1 patient treated with drainage only, and 1 patient treated with β- lactam + drainage experience recurrence after 30 d
Ruhe and Menon [25] N = 282	Retrospective/ outpatient/ United States	Community-acquired purulent <i>S aureus</i> SSTI Age: 48 (18–85)	Minocycline (PO); N = 3 or Doxycycline (PO); N = 87 DOT: 3–20 d (median 10) Incision/drainage; 77% β-lactam (PO and/or IV); N = 192 DOT: not reported Incision/drainage; 81%	Cure: 86/90 (96) 168/192 (88)	Retrospective Few patients received minocycline Clinical outcomes of minocycline/ doxycycline reported as aggregate 20 of 168 β-lactam treatment successes occurred in patients changed from β-lactam to targeted therapy based on antimicrobial susceptibility data

Table 1 continued.

Study/Sample Size	Design/ Setting	Population/Condition/Age; Mean or Median (Range), Years	Reported Treatment(s)	Outcome(s) N (%)	Potential for Bias
Rogers et al [26] N = 24	Prospective uncontrolled/ inpatient/United States	Severe (investigator reported) infections SSTI, N = 6 Age: 56 (43–77) Mixed PNA, N = 14 Age: 48 (5–84)	Minocycline (IV)	Cure: SSTI; 4/6 (67) Mixed PNA; 14/14 (100)	Uncontrolled, small sample size Heterogeneous disease states DOT: Not reported
Community-acquired pneumonia					
Kawai et al [27] N = 30	Prospective uncontrolled/ inpatient or outpatient/ Japan	<i>Mycoplasma pneumoniae</i> CAP Macrolide resistant, N = 21 Age: 8 (1–15)	Minocycline required for 15 patients with macrolide treatment failure DOT: 8–11 d (route not reported)	Defervesce within 48 H: 15/15 (100)	Uncontrolled study; only included confirmed <i>M pneumoniae</i> ; small sample size Clinical outcome assessed as presence of fever Minocycline used as secondary agent
Okada et al [28] N = 202	Prospective observational/ inpatient or outpatient/ Japan	<i>M pneumoniae</i> CAP Macrolide resistant, N = 176 Age: 8 (1–14)	Secondary agent used in macrolide resistance: Minocycline; N = 52 DOT: 2–7 d (mean 5) Doxycycline; N = 16 DOT: 3–7 d (mean 3) Macrolides; N = 13 DOT: 3–10 d (mean 6) Tosufloxacin; N = 13 DOT: 2–7 d (mean 5) (routes not reported)	Defervesce within 48 H: 47 (90) 14 (88) 6 (46) 9 (69)	Observational study; only included confirmed <i>M pneumoniae</i> Clinical outcome assessed as presence of fever Minocycline used as secondary agent
Kawai et al [29] N = 188	Prospective observational/ inpatient or outpatient/ Japan	<i>M pneumoniae</i> CAP macrolide resistant, N = 150 Age: 8 (0–15)	Definitive treatment in macrolide resistance: Minocycline, N = 38 Azithromycin, N = 27 Clarithromycin, N = 23 Tosufloxacin, N = 62 (routes not reported)	Defervesce within 48 H: 33 (87) 11 (41) 11 (48) 43 (69)	Observational study; only included confirmed <i>M pneumoniae</i> Clinical outcome assessed as presence of fever Minocycline (age ≥8)/tosufloxacin (age <8) used as definitive therapy Treatments determined by attending physician/not standardized DOT: Not reported
Miyashita et al [30] N = 73	Prospective observational/ inpatient or outpatient/ Japan	<i>M pneumoniae</i> CAP Macrolide resistant, N = 30 Age: 23 (16–45)	Initial treatment in macrolide resistance: Minocycline, N = 7 Macrolides, N = 14 Quinolones, N = 9 (All admitted patients received IV minocycline, other specifics of route not reported)	Defervesce within 48 H: 6 (85) 4 (28) 7 (77)	Observational study; only included confirmed <i>M pneumoniae</i> ; small sample size Clinical outcome assessed as presence of fever DOT: Not reported

Table 1 continued.

Study/Sample Size	Design/ Setting	Population/Condition/Age; Mean or Median (Range), Years	Reported Treatment(s)	Outcome(s) N (%)	Potential for Bias
Lyme disease					
Weber et al [31] N = 107	Prospective, nonrandomized intervention/not reported/ Germany	Early erythema migrans, N = 97 Age: Not adequately reported	Minocycline, N = 11 DOT: 10–15 d Doxy/tetracycline, N = 8 DOT: 10–14 d Penicillin (PO), N = 65 DOT: 10–14 d Penicillin (parenteral), N = 7 DOT: 10–14 d Erythromycin, N = 6 DOT: 10 d (other routes not specifically reported)	Time to cure (weeks): mean/median 7/2 19/2 22/2 7/2 2/9	Nonrandomized; small sample size Limited differentiation in outcomes between minocycline and doxycycline
Muellegger et al [32] N = 14	Prospective uncontrolled/ not reported/Austria	Erythema migrans, <i>Borrelia burgdorferi</i> DNA confirmed (57%) Age: 53 (34–79)	Minocycline (PO); N = 14 DOT: 14 d	Good clinical response: 14/14 (100)	Uncontrolled; small sample size
Breier et al [33] N = 60	Prospective open label randomized/outpatient/ Austria	Erythema migrans Age: 43 (19–80)	Minocycline, N = 30 DOT: 21 d Penicillin V, N = 30 DOT: 21 d (route not reported)	Both groups: Complete recovery; no late disease at 1 y	Withdraw due to side effects (minocycline, 12; penicillin V, 9) excluded from analysis Open label design; small sample size
Schmidt et al [34] N = 26	Prospective uncontrolled/ not reported/Austria	Erythema migrans Age: 56 (20–84)	Minocycline (PO) DOT: 14 d	8 wks post therapy: 20/22 (91) Erythema Migrans clear; 0/22 (0) Additional symptoms present	Uncontrolled; small sample size 4 patients lost to follow up at 8 wks Limited report of clinical outcomes
Stanek et al [35] N = 99	Prospective uncontrolled/ outpatient/Austria	Erythema migrans Age: 50 (10–80)	Minocycline (PO) Amoxicillin (PO) Azithromycin (PO) Doxycycline (PO) Penicillin V (PO) DOT: 2–3 wks (all treatments)	Complete resolution in all patients within 3 wks	Uncontrolled; limited report of clinical outcomes Number of patients treated with each antibiotic not reported
Glatz et al [36] N = 113	Retrospective/not reported/ Austria	Erythema migrans Age: 51 (5–78)	Minocycline (PO), N = 61* Doxycycline (PO), N = 13* β-lactam (PO/IV), N = 36 DOT: Not reported	Complete symptom resolution within 1 mo: 109/113 (96)	Retrospective; variable antibiotic treatment Limited report of clinical outcomes Clinical outcome reported as aggregate
Rickettsial infections					
Kodama et al [37] N = 28	Retrospective/inpatient/ Japan	Japanese spotted fever Age: 60 (12–78) Died before treatment, N = 1	Minocycline; N = 25 Minocycline + steroids; N = 2 (route not reported)	Cure: 25/25 (100%) 2/2 (100%)	Retrospective, small sample size Minocycline dosing not reported DOT: Not reported

Abbreviations: CAP, community-acquired pneumonia; DOT, duration of therapy; H, hours; IV, intravenous; MRSA, methicillin-resistant *S aureus*; PNA, pneumonia; PO, per oral; PRN, as needed; Q, every; SSTI, skin and soft-tissue infections; Trim/sulfa, trimethoprim/sulfamethoxazole.

* Values calculated from data presented in Table 1 of Arch Dermatol 2006;142(7):862–868.




Figure 2. Flow diagram of study selection.

erythema migrans [31–36]. Each study—including 1 prospective open-label randomized study—demonstrated high cure rates with minocycline therapy. In the randomized study, minocycline was compared with penicillin V. The dropout rate was high, with 30% (penicillin V) and 40% (minocycline) of patients stopping treatment before completing the planned 21-day course [33]. All patients that completed the course of minocycline achieved cure at the end of therapy and were symptom free at 1 year. In the most recent report, 109 of 113 (96.5%) patients treated for early erythema migrans with minocycline, doxycycline, or a β -lactam achieved complete symptom resolution by 1 month [36]. However, this report was primarily focused upon serum antibody responses and did not report cure per treatment strategy. However, >50% of the patients were treated with minocycline, and only 4 patients overall had any remaining symptoms at 1 month.

Rickettsial Disease

The 1 identified report regarding rickettsial disease was in 28 Japanese patients treated for Japanese spotted fever, the causative organism being *Rickettsia japonica* [37]. Twenty-seven (96%) patients achieved cure with minocycline therapy. One patient with fulminant disease died before administration of

minocycline. The study included 5 other patients with severe and potentially life-threatening diseases that were successfully treated with minocycline.

DISCUSSION

Skin and Soft-Tissue Infection

The data reported herein support the effectiveness of minocycline in a broad range of SSTIs. Patients that are immunocompromised or presenting with severe disease will likely be treated with nontetracycline intravenous antibiotics, in line with the current standard of care [17, 26, 62]. However, in circumstances amenable to the use of doxycycline, it appears that minocycline is more than a reasonable alternative. In addition, there are no pharmacokinetic properties, in vitro data, or in vivo data that we are aware of that portend minocycline to be inferior to doxycycline in the treatment of SSTIs. The 2011 Infectious Disease Society of America (IDSA) MRSA (methicillin-resistant *S aureus*) guideline [17] includes “doxycycline or minocycline” as A-II treatment options for empirical coverage of community-acquired MRSA SSTIs in outpatients. Furthermore, minocycline may be advantageous over doxycycline because it does not appear to be prone to inducing its own resistance [63]. These final

points are absent from the most recent SSTI guidelines from the IDSA [62], potentially omitted to aid concision because the MRSA guidelines are still considered up-to-date. Therefore, we recommend minocycline substitution for doxycycline in the treatment of SSTIs during doxycycline shortage. Considering the frequency of SSTIs [62], the substitution of minocycline is a reasonable initiative to conserve doxycycline supplies for indications with less desirable alternatives.

Community-Acquired Pneumonia

The decision to use minocycline in CAP must be considered in context of the overarching treatment recommendations for CAP [18, 64–66]. Current guidelines recommend doxycycline monotherapy as an alternative treatment only for otherwise healthy patients with low risk for drug-resistant *Streptococcus pneumoniae* (weak recommendation, level III evidence) [18]. Likewise, we found limited evidence to support minocycline monotherapy in severe infections or in confirmed *S pneumoniae* infection. The reviewed data for minocycline in CAP were positive but mostly limited to *M pneumoniae* infection. In considering the outpatient treatment of young otherwise healthy patients—where atypical organisms (primarily *M pneumoniae*) may be of more concern—minocycline could be used within the same framework in which doxycycline is recommended. Our recommendation also takes into consideration the increased vaccination for pneumococcus and the typically severe presentation of Legionnaires' disease [66]. Overall, empirical tetracycline monotherapy should be reserved for uncomplicated cases of CAP [18].

Contrary to this narrow recommendation, there is compelling data to support minocycline's use in CAP specifically caused by macrolide-resistant *M pneumoniae* [27–30]. Considering the increased incidence of macrolide-resistance *M pneumoniae* in the United States and globally [67], there will likely be an increased need for tetracycline therapy in CAP. Furthermore, there is increased attention to the cardiovascular risk profile of macrolides and fluoroquinolones, both of which are commonly used for empirical coverage of atypical pathogens in CAP [68, 69]. For patients with underlying cardiac comorbidities, tetracyclines, including minocycline, may be preferred as adjuncts to antipneumococcal β -lactams. In circumstances in which there is concern for treating macrolide-resistant *M pneumoniae* or when doxycycline would be preferred for empirical atypical coverage, we recommend substituting minocycline for doxycycline.

Lyme Disease Prophylaxis

At this time, the CDC only recommends doxycycline as an option for Lyme disease prophylaxis due to lack of evidence with other medications. The CDC specifically recommends against single-dose amoxicillin due to its short half-life (eg, approximately 1 hour) [1, 70]. However, minocycline has an extended

half-life similar to doxycycline (eg, >12 hours) [7, 9]. Minocycline appears effective in the treatment of early Lyme disease [31–36]. Unfortunately, we found no data regarding minocycline for Lyme disease prophylaxis following tick bite. However, most studies regarding prophylaxis are equivocal due to the low event rate [71–75]. The most recent guideline from the IDSA includes an option for prophylaxis with single-dose doxycycline in patients meeting strict criteria [76]. Therefore, when prophylaxis is indicated in the absence of doxycycline, we recommend clinicians consider minocycline and exercise shared decision making [77]. We recommend that this conversation include at least 5 key points: (1) the overall risk of developing Lyme disease is low and forgoing prophylaxis may be reasonable; (2) there are effective treatments for early Lyme disease; (3) the benefit of antibiotic prophylaxis is small and may be offset by the risk for adverse effects with antibiotic treatment; (4) doxycycline is usually recommended, however, if unavailable, minocycline is a similar but less studied antibiotic; and (5) although minocycline may work better, as well, or not as well other antibiotics, it is suggested as a potential alternative because it works similarly to doxycycline, and it has been shown to be effective in patients who have developed Lyme disease.

Rickettsial Diseases

The literature to support the use of minocycline in rickettsial diseases is severely limited. Although the included report of Japanese spotted fever had a rate of life-threatening disease on par with Rocky Mountain spotted fever—the most common rickettsial disease in the United States—it is difficult to use these data as a surrogate. Rocky Mountain spotted fever is a circumstance that warrants retaining a supply of doxycycline in endemic areas. However, the CDC did not definitively recommend alternative therapy should doxycycline be entirely unavailable [1]. Therefore, we pose that it is worthy to consider minocycline's place in therapy for Rocky Mountain spotted fever—given its lethality—in the scenario of complete doxycycline unavailability.

Older and in vitro data demonstrate that tetracycline may be a potential alternative to doxycycline [78–80]. To our knowledge, there are no reports of increasing resistance of *Rickettsia rickettsii* to any tetracycline antibiotic. Considering minocycline and doxycycline's similar pharmacokinetic and susceptibility profiles, we portend minocycline to be a potential alternative, despite the dearth of clinical data. Important in this consideration is that further alternatives may be considerably less desirable. The CDC mentions the potential use of chloramphenicol as an alternative to doxycycline [1]. However, the CDC rightly notes that chloramphenicol is associated with a greater mortality risk compared with treatment regimens that include a tetracycline. This fact is supported by 2 large surveillance studies that demonstrate chloramphenicol monotherapy to be statistically associated with fatal disease compared with treatment with any tetracycline as monotherapy or with any tetracycline

in combination with chloramphenicol [81, 82]. Unfortunately, these studies did not delineate the different tetracycline agents used. Considering the lethality of Rocky Mountain spotted fever and the potential inferiority of chloramphenicol monotherapy, we recommend treatment with either minocycline or tetracycline in combination with chloramphenicol over chloramphenicol monotherapy in the absence of doxycycline. The limitations of these data are significant and more research—including observational and retrospective reports—is greatly needed. We make this tenuous recommendation because there is the potential for this circumstance to occur and no direct guidance from the CDC or other authorities.

CONCLUSIONS

In conclusion, drug shortages interfere with the management of infectious diseases and necessitate the use of less familiar alternatives. This systematic review supports the use of minocycline as a substitute for doxycycline in SSTIs, an alternative in the outpatient treatment of CAP in young otherwise healthy patients (with more evidence in macrolide-resistant *M pneumoniae*), an alternative to doxycycline for Lyme disease prophylaxis (should prophylaxis be strongly desired and doxycycline is unavailable), and a last alternative in select rickettsial diseases should doxycycline be entirely unavailable. Given the myriad of indications for which doxycycline can be used, further research, review, and guidance are needed to prepare practitioners, institutions, and health systems to provide adequate care in the face of tetracycline shortages and antibiotic shortages in general.

Acknowledgments

Disclaimer. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

- Centers for Disease Control and Prevention. Nationwide Shortage of Doxycycline: Resources for Providers and Recommendations for Patient Care. Available at: <http://emergency.cdc.gov/han/han00349.asp>. Accessed 7 August 2015.
- Quadri F, Mazer-Amirshahi M, Fox ER, et al. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice. *Clin Infect Dis* **2015**; 60:1737–42.
- American Society of Health-System Pharmacists. ASHP Drug Shortages Resource Center. Available at: <http://www.ashp.org/menu/DrugShortages>. Accessed 20 August 2015.
- United States Senate Committee on Health, Education, Labor and Pensions. Subcommittee on Primary Health and Aging. Why are some generic drugs skyrocketing in price? **2015**. Available at: <http://www.help.senate.gov/hearings/why-are-some-generic-drugs-skyrocketing-in-priced>. Accessed 20 August 2015.
- Gundlapalli AV, Beekmann SE, Graham DR, Polgreen PM. Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists. *Diagn Microbiol Infect Dis* **2013**; 75:256–9.
- AARP Public Policy Institute. Trends in Retail Prices of Generic Prescription Drugs Widely Used by Older Americans, 2006 to 2013. Available at: <http://www.aarp.org/content/dam/aarp/ppi/2015/trends-in-retail-prices-of-generic-prescription-drugs.pdf>. Accessed 9 December 2015.
- Minocin® [package insert]. Monza, Italy: Triax Pharmaceuticals; **2010**.
- Eisen DP. Tetracycline. In: Grayson LM, Kucers A, Crowe S, et al, eds. *Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs*. Boca Raton, FL: CRC Press, **2010**:843–50.
- Vibramycin® [package insert]. New York, NY: Pfizer Laboratories, **2015**.
- Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. *Clin Pharmacokinet* **1988**; 15:355–66.
- Alestig K. Studies on doxycycline during intravenous and oral treatment with reference to renal function. *Scand J Infect Dis* **1973**; 5:193–8.
- Alestig K. Studies on the intestinal excretion of doxycycline. *Scand J Infect Dis* **1974**; 6:265–71.
- Mahon WA, Johnson GE, Endrenyl L, et al. The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function. *Scand J Infect Dis Suppl* **1976**; 9:24–31.
- Steigbigel NH, Reed CW, Finland M. Absorption and excretion of five tetracycline analogues in normal young men. *Am J Med Sci* **1968**; 255:296–312.
- Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. *Clin Ther* **2005**; 27:1329–42.
- Falagas ME, Vardakas KZ, Kapaskelis A, et al. Tetracyclines for multi-drug-resistant *Acinetobacter baumannii* infections. *Int J Antimicrob Agents* **2015**; 45:455–60.
- Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis* **2011**; 52:285–92.
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* **2007**; 44:S27–72.
- Cappel R, Klastersky J. Bacteriologic and clinical evaluation of minocycline, a new tetracycline. *Curr Ther Res Clin Exp* **1971**; 13:227–33.
- Phair JP, Hartman RE, Carleton J. Evaluation of the efficacy of minocycline therapy for staphylococcal soft-tissue infection. *Antimicrob Agents and Chemother* **1974**; 6:551–3.
- Raff MJ, Rogers J, Barnwell PA, Waterman N. Minocycline in staphylococcal soft-tissue infections. *Arch Dermatol* **1975**; 111:874–6.
- Clumek N, Marcelis L, Amiri-Lamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. *J Antimicrob Chemother* **1984**; 13:17–22.
- Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant *Staphylococcus aureus* infections: case series and review of the literature. *Clin Infect Dis* **2005**; 40:1429–34.
- Barnes EV II, Dooley DP, Hepburn MJ, Baum SE. Outcomes of community-acquired, methicillin-resistant *Staphylococcus aureus*, soft tissue infections treated with antibiotics other than vancomycin. *Mil Med* **2006**; 171:504–7.
- Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* **2007**; 51:3298–303.
- Rogers JH, Barnwell PA, Waterman NG, et al. Clinical evaluation of intravenous minocycline. *Int J Clin Pharmacol Biopharm* **1977**; 15:194–8.
- Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant *Mycoplasma pneumoniae* pneumonia in paediatric patients. *Respirology* **2012**; 17:354–62.

28. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant *Mycoplasma pneumoniae* infection in a 2011 outbreak among Japanese children. *Clin Infect Dis* **2012**; 55:1642–9.
29. Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant *Mycoplasma pneumoniae* pneumonia in pediatric patients. *Antimicrob Agents Chemother* **2013**; 57:2252–8.
30. Miyashita N, Akaike H, Teranishi H, et al. Macrolide-resistant *Mycoplasma pneumoniae* pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. *Antimicrob Agents Chemother* **2013**; 57:5181–5.
31. Weber K, Neubert U, Thurmayer R. Antibiotic therapy in early erythema migrans disease and related disorders. *Zentralbl Bakteriol Mikrobiol Hyg A* **1987**; 263:377–88.
32. Muellegger RR, Zochling N, Soyer HP, et al. No detection of *Borrelia burgdorferi*-specific DNA in erythema migrans lesions after minocycline treatment. *Arch Dermatol* **1995**; 131:678–82.
33. Breier F, Kunz G, Klade H, et al. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. *Infection* **1996**; 24:69–72.
34. Schmidt B, Muellegger RR, Stockenhuber C, et al. Detection of *Borrelia burgdorferi*-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy. *J Clin Microbiol* **1996**; 34:1359–63.
35. Stanek G, Breier F, Menzinger G, et al. Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three *Borrelia* species. *Wien Klin Wochenschr* **1999**; 111:951–6.
36. Glatz M, Golestani M, Kerl H, Muellegger RR. Clinical relevance of different IgG and IgM serum antibody responses to *Borrelia burgdorferi* after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. *Arch Dermatol* **2006**; 142:862–8.
37. Kodama K, Senba T, Yamauchi H, et al. Clinical study of Japanese spotted fever and its aggravating factors. *J Infect Chemother* **2003**; 9:83–7.
38. Tenjin Y, Wada M, Oomura N, Higuchi S. [First case report of fatal Japanese spotted fever in Kumamoto Prefecture and the investigation of severe cases in Kamiyamakusa City]. *Kansenshogaku Zasshi* **2014**; 88:700–3.
39. Miyashita N, Kawai Y, Akaike H, et al. Atelectasis caused by macrolide-resistant *Mycoplasma pneumoniae* pneumonia in an adult patient. *J Infect Chemother* **2013**; 19:1161–6.
40. Nakata R, Motomura M, Tokuda M, et al. A case of Japanese spotted fever complicated with central nervous system involvement and multiple organ failure. *Intern Med* **2012**; 51:783–6.
41. Inamo Y, Ishizuka Y, Hashimoto K, et al. A 7-year-old girl with subcutaneous emphysema, pneumomediastinum, pneumothorax, and pneumoretroperitoneum caused by *Mycoplasma pneumoniae* pneumonia. *J Infect Chemother* **2012**; 18:247–50.
42. Kondo M, Kurokawa I, Yamanaka K, et al. Japanese spotted fever with acute hepatic failure: was it associated with Epstein-Barr virus? *Int J Dermatol* **2010**; 49:1403–5.
43. Kondo M, Kurokawa I, Yamanaka K, et al. Topical treatment with incision and antiseptic may prevent the severity of Japan spotted fever. *J Dermatol* **2010**; 37:835–6.
44. Takahashi T, Morozumi M, Okada T, et al. Prolonged *Mycoplasma pneumoniae* infection in an elderly patient with community-acquired pneumonia. *J Infect Chemother* **2009**; 15:243–7.
45. Wada K, Sakaeda H, Aono R, Chiya S. Fulminant Japanese spotted fever—the second fatal case in Japan. *Kansenshogaku Zasshi* **2008**; 82:77–81.
46. Tsai YS, Wu YH, Kao PT, Lin YC. African tick bite fever. *J Formos Med Assoc* **2008**; 107:73–6.
47. Nakayama E, Hasegawa K, Morozumi M, et al. Rapid optimization of antimicrobial chemotherapy given to pediatric patients with community-acquired pneumonia using PCR techniques with serology and standard culture. *J Infect Chemother* **2007**; 13:305–13.
48. Seki M, Ikari N, Yamamoto S, et al. Severe Japanese spotted fever successfully treated with fluoroquinolone. *Intern Med* **2006**; 45:1323–6.
49. Noji Y, Takada N, Ishiguro F, et al. The first reported case of spotted fever in Fukui Prefecture, the northern part of central Japan. *Jpn J Infect Dis* **2005**; 58:112–4.
50. Yanagi S, Ashitani J, Arimura Y, et al. A case of severe *Chlamydia pneumoniae* pneumonia requiring mechanical ventilation and complicated with disseminated intravascular coagulation. *Nihon Kokyuki Gakkai Zasshi* **2003**; 41:840–5.
51. Kodama K, Senba T, Yamauchi H, et al. Japanese spotted fever associated with multiorgan failure. *J Infect Chemother* **2001**; 7:247–50.
52. Iwasaki H, Mahara F, Takada N, et al. Fulminant Japanese spotted fever associated with hypercytokinemia. *J Clin Microbiol* **2001**; 39:2341–3.
53. Tsai KH, Lu HY, Huang JH, et al. African tick bite fever in a Taiwanese traveler returning from South Africa: molecular and serologic studies. *Am J Trop Med Hyg* **2009**; 81:735–9.
54. Johnson SE, Klein GC, Schmid GP, Feeley JC. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. *Yale J Biol Med* **1984**; 57:549–53.
55. Miyamura S, Ohta T, Tamura A. Comparison of in vitro susceptibilities of *Rickettsia prowazekii*, *R. rickettsii*, *R. sibirica* and *R. tsutsugamushi* to antimicrobial agents. *Nihon Saikingaku Zasshi* **1989**; 44:717–21.
56. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete *Borrelia burgdorferi*. *J Infect Dis* **2009**; 199:1379–88.
57. Li M, Masuzawa T, Wang J, et al. In-vitro and in-vivo antibiotic susceptibilities of Lyme disease *Borrelia* isolated in China. *J Infect Chemother* **2000**; 6:65–7.
58. Fujita H, Yamada K, Kurita T, et al. In vitro and in vivo antibiotic susceptibility of Lyme disease *Borrelia* isolated from the ixodid tick in Japan. *J Dermatol* **1995**; 22:935–8.
59. Cunha BA. Minocycline, often forgotten but preferred to trimethoprim-sulfamethoxazole or doxycycline for the treatment of community-acquired methicillin-resistant *Staphylococcus aureus* skin and soft-tissue infections. *Int J Antimicrob Agents* **2013**; 42:497–9.
60. Cunha BA. Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant *Staphylococcus aureus* (MRSA) skin and soft tissue infections (SSTIs). *Eur J Clin Microbiol Infect Dis* **2014**; 33:1869–71.
61. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant *Staphylococcus aureus* at an ambulatory clinic. *Antimicrob Agents Chemother* **2007**; 51:423–8.
62. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* **2014**; 59:147–59.
63. Schwartz BS, Graber CJ, Diep BA, et al. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant *Staphylococcus aureus* clone USA300. *Clin Infect Dis* **2009**; 48:1483–4.
64. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clin Infect Dis* **2011**; 53:e25–76.
65. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* **2014**; 371:1619–28.
66. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. *N Engl J Med* **2014**; 370:543–51.
67. Zheng X, Lee S, Selvarangan R, et al. Macrolide-resistant *Mycoplasma pneumoniae*, United States. *Emerg Infect Dis* **2015**; 21:1470–2.
68. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. *N Engl J Med* **2012**; 366:1881–90.
69. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. *Ann Fam Med* **2014**; 12:121–7.

70. Amoxil* [package insert]. Research Triangle Park, NC: GlaxoSmith Kline; **2006**.
71. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. *N Engl J Med* **1992**; 327:1769–73.
72. Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. *N Engl J Med* **1992**; 327:534–41.
73. Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. *Am J Dis Child* **1993**; 147:945–7.
74. Costello CM, Steere AC, Pinkerton RE, Feder HM Jr. A prospective study of tick bites in an endemic area for Lyme disease. *J Infect Dis* **1989**; 159:136–9.
75. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an *Ixodes scapularis* tick bite. *N Engl J Med* **2001**; 345:79–84.
76. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* **2006**; 43:1089–134.
77. Hoffmann TC, Montori VM, Del Mar C. The connection between evidence-based medicine and shared decision making. *JAMA* **2014**; 312:1295–6.
78. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis—United States: a practical guide for physicians and other health-care and public health professionals. *MMWR Recomm Rep* **2006**; 55:1–27.
79. Raoult D, Roussellier P, Vestris G, Tamalet J. In vitro antibiotic susceptibility of *Rickettsia rickettsii* and *Rickettsia conorii*: plaque assay and microplaque colorimetric assay. *J Infect Dis* **1987**; 155:1059–62.
80. Raoult D, Drancourt M. Antimicrobial therapy of rickettsial diseases. *Antimicrob Agents Chemother* **1991**; 35:2457–62.
81. Holman RC, Paddock CD, Curns AT, et al. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. *J Infect Dis* **2001**; 184:1437–44.
82. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981–1992: epidemiologic summary and evaluation of risk factors for fatal outcome. *Am J Trop Med Hyg* **1995**; 52:405–13.